FDA scrutiny
FDA’s Makary defends drug rejections amid backlash
The FDA commissioner told CNBC he stands with agency scientists after criticism over recent decisions, including the rejection of Replimune’s melanoma drug candidate
Read verified news on BetaVoices covering Drug approvals, with reporting, context, and related developments.
FDA scrutiny
The FDA commissioner told CNBC he stands with agency scientists after criticism over recent decisions, including the rejection of Replimune’s melanoma drug candidate